| ITEM 1. |
|
Name and Address of Company |
|
|
|
|
|
|
|
Aurinia Pharmaceuticals Inc. (the “Company”)
|
|
|
|
1203 – 4464 Markham Street
|
|
|
|
Victoria, BC V8Z 7X8
|
|
|
|
|
| ITEM 2. |
|
Date of Material Change
|
|
|
|
|
|
|
|
February 6, 2017 |
|
|
|
|
|
ITEM 3.
|
|
News Release |
|
|
|
|
|
|
|
A news release relating to the material change described herein was disseminated on February 6, 2017 via Business Wire. |
|
|
|
|
|
ITEM 4.
|
|
Summary of Material Change
|
|
|
|
|
|
|
|
The Company announced the resignation of Charles Rowland as Chief Executive Officer and director of the Company and the appointment of Dr. Richard M. Glickman, the Company's founder and Chairman of the Board, as the Company’s Chairman and Chief Executive Officer, effective February 6, 2017. |
|
|
|
|
| ITEM 5. |
|
Full Description of Material Change |
|
|
|
|
|
|
|
The Company announced the resignation of Charles Rowland as Chief Executive Officer and director of the Company and the appointment of Dr. Richard M. Glickman, the Company's founder and Chairman of the Board, as the Company’s Chairman and Chief Executive Officer, effective February 6, 2017.
|
|
|
|
|
|
ITEM 5.2.
|
|
Disclosure of Restructuring Transactions
|
|
|
|
|
|
|
|
Not applicable. |
|
|
|
|
|
ITEM 6.
|
|
Reliance on Subsection 7.1(2) of National Instrument 51-102
|
|
|
|
|
|
|
|
Not applicable.
|
|
|
|
|
|
ITEM 7.
|
|
Omitted Information |
|
|
|
|
|
|
|
There are no significant facts required to be disclosed herein which have been omitted.
|
|
|
|
|
| ITEM 8. |
|
Executive Officer |
|
|
|
|
|
|
|
For further information, please contact:
|
|
|
|
|
|
|
|
Michael R. Martin, Chief Operating Officer
|
|
|
|
250-415-9713 |
|
|
|
mmartin@auriniapharma.com
|
|
|
|
|
| ITEM 9. |
|
Date of Report
|
|
|
|
|
|
|
|
February 16, 2017 |